Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)

e.g. "Sirolimus", "アダリムマブ", "MAP2K"

ABCDEFGH I JKLMNOPQRSTUVWXYZother

42 / 286 pathways

No. KEGG PATHWAY   💬 Info on mouse-over
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES
💬 Info on mouse-over
KEGG DRUG
💬 Info on mouse-over
DrugBank 指定難病告示番号
💬 Info on mouse-over
1 African trypanosomiasis 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
2 AGE-RAGE signaling pathway in diabetic complications 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
3 Alzheimer disease 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
4 Amoebiasis 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
5 Antifolate resistance 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
6 C-type lectin receptor signaling pathway 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
7 Chagas disease 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
8 Coronavirus disease - COVID-19 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
9 Cytokine-cytokine receptor interaction 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
10 Cytosolic DNA-sensing pathway 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
11 Fluid shear stress and atherosclerosis 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
12 Graft-versus-host disease 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
13 Hematopoietic cell lineage 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
14 Herpes simplex virus 1 infection 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
15 Human cytomegalovirus infection 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
16 IL-17 signaling pathway 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
17 Inflammatory bowel disease 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
18 Inflammatory mediator regulation of TRP channels 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
19 Influenza A 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
20 Legionellosis 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
21 Leishmaniasis 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
22 Malaria 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
23 MAPK signaling pathway 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
24 Measles 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
25 Necroptosis 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
26 NF-kappa B signaling pathway 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
27 NOD-like receptor signaling pathway 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
28 Non-alcoholic fatty liver disease 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
29 Osteoclast differentiation 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
30 Pathogenic Escherichia coli infection 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
31 Pathways of neurodegeneration - multiple diseases 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
32 Pertussis 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
33 Prion disease 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
34 Rheumatoid arthritis 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
35 Salmonella infection 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
36 Shigellosis 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
37 Th17 cell differentiation 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
38 TNF signaling pathway 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
39 Toll-like receptor signaling pathway 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
40 Tuberculosis 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
41 Type I diabetes mellitus 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
42 Yersinia infection 💬
1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬